Afficher la notice abrégée

Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience

dc.rights.licenseopenen_US
hal.structure.identifierInstitut Necker Enfants-Malades [INEM - UM 111 (UMR 8253 / U1151)]
hal.structure.identifierInstitut Mondor de Recherche Biomédicale [IMRB]
dc.contributor.authorCRICKX, Etienne
hal.structure.identifierCentre d'Immunologie de Marseille - Luminy [CIML]
dc.contributor.authorEBBO, Mikael
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorRIVIÈRE, Etienne
dc.contributor.authorSOUCHAUD-DEBOUVERIE, Odile
dc.contributor.authorTERRIOU, Louis
hal.structure.identifierCentre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
dc.contributor.authorAUDIA, Sylvain
hal.structure.identifierCHU Estaing [Clermont-Ferrand]
dc.contributor.authorRUIVARD, Marc
hal.structure.identifierCentre Hospitalier Edouard Herriot-Lyon
dc.contributor.authorASLI, Bouchra
hal.structure.identifierCHU Amiens-Picardie
hal.structure.identifierHEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
dc.contributor.authorMAROLLEAU, Jean‐pierre
hal.structure.identifierService de médecine interne [Med Int - BESANCON]
dc.contributor.authorMÉAUX-RUAULT, Nadine
hal.structure.identifierHospices Civils de Lyon [HCL]
hal.structure.identifierHôpital de la Croix-Rousse [CHU - HCL]
hal.structure.identifierUniversité Claude Bernard Lyon 1 [UCBL]
dc.contributor.authorGERFAUD-VALENTIN, Mathieu
dc.contributor.authorAUDEGUY, Philippe
dc.contributor.authorHAMIDOU, Mohamed
hal.structure.identifierMedipole De Savoie
dc.contributor.authorCORM, Selim
hal.structure.identifierService de Médecine Interne [Pau]
dc.contributor.authorDELBREL, Xavier
hal.structure.identifierService d'hématologie
dc.contributor.authorFONTAN, Jean
hal.structure.identifierCHU Amiens-Picardie
hal.structure.identifierHEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
dc.contributor.authorLEBON, Delphine
dc.contributor.authorMAUSSERVEY, Christelle
hal.structure.identifierCentre Hospitalier Universitaire de Toulouse [CHU Toulouse]
dc.contributor.authorMOULIS, Guillaume
dc.contributor.authorLIMAL, Nicolas
dc.contributor.authorMICHEL, Marc
dc.contributor.authorGODEAU, Bertrand
hal.structure.identifierMolecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) [Inserm U955]
dc.contributor.authorMAHÉVAS, Matthieu
dc.date.accessioned2023-07-18T07:11:29Z
dc.date.available2023-07-18T07:11:29Z
dc.date.issued2023-05
dc.identifier.issn0007-1048en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/183410
dc.description.abstractEnCombining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO-RA) and splenectomy. We conducted a retrospective, multicenter, observational study including multirefractory ITP patients who received a combination of a TPO-RA and an immunosuppressive drug. We included 39 patients (67% women, median age 59 years [range 21-96]), with a median ITP duration of 57 months [3-393] and a median platelet count at initiation of 10 × 109 /L [1-35]. The combination regimen was given for a median duration of 12 months [1-103] and included eltrombopag (51%) or romiplostim (49%), associated with mycophenolate mofetil (54%), azathioprine (36%), cyclophosphamide (5%), cyclosporin (3%) or everolimus (3%). Overall, 30 patients (77%) achieved at least a response (platelet count ≥30 × 109 /L and at least doubling baseline during at least 3 months), including 24 complete responses (platelet count >100 × 109 /L during at least 3 months) with a median time to response of 30 days [7-270] and a median duration of response of 15 months [4-63]. Severe adverse event related to ITP treatment was observed in 31%. In conclusion, this study confirms that some patients with multirefractory ITP can achieve long lasting response with this combination.
dc.language.isoENen_US
dc.subjectArticle clinique
dc.subject.enITP
dc.subject.enTPO-RA
dc.subject.encombination therapy
dc.subject.enimmunosuppressive drug
dc.title.enCombining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bjh.18893en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
bordeaux.journalBritish Journal of Haematologyen_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04113859
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Haematology&rft.date=2023-05&rft.eissn=0007-1048&rft.issn=0007-1048&rft.au=CRICKX,%20Etienne&EBBO,%20Mikael&RIVI%C3%88RE,%20Etienne&SOUCHAUD-DEBOUVERIE,%20Odile&TERRIOU,%20Louis&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée